Read More

EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.

SABS

Read More

EXCLUSIVE: Cannabis CEOs Address How To Attract Investors Amid Changing Regulations

"The right investors are not scared by the complexity of cannabis regulations," TILT Holdings (CSE: TILT) (OTC: TLLTF) CEO Tim Conder said at the Benzinga Cannabis Capital Conference.

CSE:TILT

Read More

Soleno Therapeutics Announces Proposed Public Offering Of Common Stock And/Or Pre-Funded Warrants; No Size Disclosed And A $30M Concurrent Private Placement Of Common Stock And/Or Pre-Funded Warrants

Soleno Therapeutics, Inc. (NASDAQ:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to

SLNO